David A. Siegel Glycomimetics Inc Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Glycomimetics Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 248,958 shares of GLYC stock, worth $57,260. This represents 0.0% of its overall portfolio holdings.
Number of Shares
248,958
Previous 108,800
128.82%
Holding current value
$57,260
Previous $30,000
40.0%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding GLYC
# of Institutions
36Shares Held
17.8MCall Options Held
0Put Options Held
0-
Bvf Inc San Francisco, CA9.54MShares$2.2 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.67MShares$614,1470.0% of portfolio
-
Siren, L.L.C. New York, NY1.97MShares$451,9760.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny781KShares$179,6530.0% of portfolio
-
Black Rock Inc. New York, NY723KShares$166,3320.0% of portfolio
About GLYCOMIMETICS INC
- Ticker GLYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,423,900
- Market Cap $12.1M
- Description
- GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...